Elisa Arribas-Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisa Arribas-Rodríguez has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- David Bernardo
Mucosal Immunology Lab, Instituto de Biología y Genética Molecular (IBGM, Universidad de Valladolid-CISC), Valladolid, Spain
9 shared publications - Aida Fiz-López
Mucosal Immunology Laboratory, Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Sanz y Forés 3, Valladolid 47003, Spain
6 shared publications Eduardo Arranz
Mucosal Immunology Lab Instituto Biomedicina y Genética Molecular de Valladolid (IBGM Universidad De Valladolid‐CISC) Valladolid Spain
5 shared publicationsÁngel De Prado
Mucosal Immunology Lab Instituto Biomedicina y Genética Molecular de Valladolid (IBGM Universidad De Valladolid‐CISC) Valladolid Spain
5 shared publications- Paloma Cal-Sabater
Mucosal Immunology Laboratory Institute of Biomedicine and Molecular Genetics (IBGM), Universidad de Valladolid‐CSIC Valladolid Spain
4 shared publications Alejandro Romero
Servicio De Cirugía General y Del Aparato Digestivo. Hospital Clínico Universitario Valladolid Spain
3 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Wiley in Immunology
- Vol. 178 (4) , 685-703
High‐Dimensional Immune Profiling Identifies Circulating NKT ‐Like Cells Associated With Severity Outcome in Acute Pancreatitis at Disease Onset
Acute pancreatitis (AP) patients can be classified into mild or severe outcome based on the presence of organ failure days during hospitalization. However, there are no biomarkers that can predict severity outcome. This study aim is to perform an unbiased characterization of the circulating immunome of AP patients at hospital admission aiming to identify novel biomarkers which could predict disease outcome prior to the onset of organ damage and clinical deterioration. Peripheral blood mononuclear cells (PBMC) were collected from newly hospitalized AP patients. Based on their evolution, patients were classified following the Modified Atlanta classification into mild acute pancreatitis (mAP) ( n = 20) as well as moderately and/or severe acute pancreatitis (ms‐sAP) ( n = 20). PBMC were analysed by high‐dimensional spectral cytometry with unsupervised dimensionality reduction and clustering algorithms based on the subsequent outcome of the patients. Results were further validated by classical gating and functional approaches with a smaller cohort ( n = 8 mAP and n = 8 ms‐sAP). A total of 120 different immune cell clusters were identified and characterized in AP patients at hospitalization. Following computational analysis and classical gating validation approaches, circulating CD2 + CD8 dim NKT‐Like cells were found to be specifically reduced in ms‐sAP patients. Moreover, NKT‐Like cell subsets from these patients displayed an IL‐15 induced expansion of NKG2a and NKp30 referred to mAP. Patients with AP at hospitalization with subsequent ms‐sAP display a specific reduction of NKT‐Like cells coupled with an expanded function. Hence, quantifying the phenotype and/or function of circulating NKT‐Like cells during hospital admission could serve as a predictive biomarker for AP severity, aiding in early stratification and personalized treatment strategies.
- 12 May 2026
- Published by Wiley in Immunology
- Vol. 178 (4) , 685-703
Open AccessHigh‐Dimensional Immune Profiling Identifies Circulating NKT ‐Like Cells Associated With Severity Outcome in Acute Pancreatitis at Disease Onset
Acute pancreatitis (AP) patients can be classified into mild or severe outcome based on the presence of organ failure days during hospitalization. However, there are no biomarkers that can predict severity outcome. This study aim is to perform an unbiased characterization of the circulating immunome of AP patients at hospital admission aiming to identify novel biomarkers which could predict disease outcome prior to the onset of organ damage and clinical deterioration. Peripheral blood mononuclear cells (PBMC) were collected from newly hospitalized AP patients. Based on their evolution, patients were classified following the Modified Atlanta classification into mild acute pancreatitis (mAP) ( n = 20) as well as moderately and/or severe acute pancreatitis (ms‐sAP) ( n = 20). PBMC were analysed by high‐dimensional spectral cytometry with unsupervised dimensionality reduction and clustering algorithms based on the subsequent outcome of the patients. Results were further validated by classical gating and functional approaches with a smaller cohort ( n = 8 mAP and n = 8 ms‐sAP). A total of 120 different immune cell clusters were identified and characterized in AP patients at hospitalization. Following computational analysis and classical gating validation approaches, circulating CD2 + CD8 dim NKT‐Like cells were found to be specifically reduced in ms‐sAP patients. Moreover, NKT‐Like cell subsets from these patients displayed an IL‐15 induced expansion of NKG2a and NKp30 referred to mAP. Patients with AP at hospitalization with subsequent ms‐sAP display a specific reduction of NKT‐Like cells coupled with an expanded function. Hence, quantifying the phenotype and/or function of circulating NKT‐Like cells during hospital admission could serve as a predictive biomarker for AP severity, aiding in early stratification and personalized treatment strategies.
- Open Access
- 17 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106731
Persistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID
- 17 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106731
Open AccessPersistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID
- Open Access
- 24 February 2026
- Published by Wiley in European Journal of Immunology
- Vol. 56 (2)
Type 1 and CD103 + Type 2 Conventional Dendritic Cells Are Decreased in Active Patients with Ulcerative Colitis but Not with Crohn's Disease
This study aimed to characterize human intestinal conventional dendritic cells (cDCs) in health and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Three cDC subsets (CD103 − cDC2, CD103 + cDC2, and cDC1) were identified from lamina propria mononuclear cells. Their phenotype and function were analyzed in healthy and IBD‐inflamed gut tissues. In the healthy gut, cDC2 predominated over cDC1, with CD103 + cDC2 dominating the duodenum and CD103 − cDC2 prevalent in the ileum and colon. CD103 + cDC2 expressed higher PD‐L1 and produced more IL‐10. In culture, CD103 + cDC2 increased proportionally unless inhibited by LPS. All subsets induced IL‐10 + helper T‐cell differentiation, with ileal cDCs being more stimulatory than colonic ones. In IBD, cDCs showed constitutively lower SIRPα expression across conditions. Notably, UC‐inflamed colon exhibited reduced cDC1 and CD103 + cDC2, while CD‐inflamed colon maintained these subsets but showed increased T‐cell stimulation and IL‐17 + T‐cell priming. Intestinal cDC subsets prime IL‐10 + helper T‐cells in health. In UC, reduced cDC1 and CD103 + cDC2 in inflamed mucosa contrast with CD, suggesting distinct pathogenic mechanisms that could inform targeted therapies.
- 24 February 2026
- Published by Wiley in European Journal of Immunology
- Vol. 56 (2)
Open AccessType 1 and CD103 + Type 2 Conventional Dendritic Cells Are Decreased in Active Patients with Ulcerative Colitis but Not with Crohn's Disease
This study aimed to characterize human intestinal conventional dendritic cells (cDCs) in health and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Three cDC subsets (CD103 − cDC2, CD103 + cDC2, and cDC1) were identified from lamina propria mononuclear cells. Their phenotype and function were analyzed in healthy and IBD‐inflamed gut tissues. In the healthy gut, cDC2 predominated over cDC1, with CD103 + cDC2 dominating the duodenum and CD103 − cDC2 prevalent in the ileum and colon. CD103 + cDC2 expressed higher PD‐L1 and produced more IL‐10. In culture, CD103 + cDC2 increased proportionally unless inhibited by LPS. All subsets induced IL‐10 + helper T‐cell differentiation, with ileal cDCs being more stimulatory than colonic ones. In IBD, cDCs showed constitutively lower SIRPα expression across conditions. Notably, UC‐inflamed colon exhibited reduced cDC1 and CD103 + cDC2, while CD‐inflamed colon maintained these subsets but showed increased T‐cell stimulation and IL‐17 + T‐cell priming. Intestinal cDC subsets prime IL‐10 + helper T‐cells in health. In UC, reduced cDC1 and CD103 + cDC2 in inflamed mucosa contrast with CD, suggesting distinct pathogenic mechanisms that could inform targeted therapies.
- Open Access
- 1 February 2026
- Vol. 56 (2) , e70118
Type 1 and CD103+ Type 2 Conventional Dendritic Cells Are Decreased in Active Patients with Ulcerative Colitis but Not with Crohn's Disease.
This study aimed to characterize human intestinal conventional dendritic cells (cDCs) in health and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Three cDC subsets (CD103- cDC2, CD103+ cDC2, and cDC1) were identified from lamina propria mononuclear cells. Their phenotype and function were analyzed in healthy and IBD-inflamed gut tissues. In the healthy gut, cDC2 predominated over cDC1, with CD103+ cDC2 dominating the duodenum and CD103- cDC2 prevalent in the ileum and colon. CD103+ cDC2 expressed higher PD-L1 and produced more IL-10. In culture, CD103+ cDC2 increased proportionally unless inhibited by LPS. All subsets induced IL-10+ helper T-cell differentiation, with ileal cDCs being more stimulatory than colonic ones. In IBD, cDCs showed constitutively lower SIRPα expression across conditions. Notably, UC-inflamed colon exhibited reduced cDC1 and CD103+ cDC2, while CD-inflamed colon maintained these subsets but showed increased T-cell stimulation and IL-17+ T-cell priming. Intestinal cDC subsets prime IL-10+ helper T-cells in health. In UC, reduced cDC1 and CD103+ cDC2 in inflamed mucosa contrast with CD, suggesting distinct pathogenic mechanisms that could inform targeted therapies.
- 1 February 2026
- Vol. 56 (2) , e70118
Open AccessType 1 and CD103+ Type 2 Conventional Dendritic Cells Are Decreased in Active Patients with Ulcerative Colitis but Not with Crohn's Disease.
This study aimed to characterize human intestinal conventional dendritic cells (cDCs) in health and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Three cDC subsets (CD103- cDC2, CD103+ cDC2, and cDC1) were identified from lamina propria mononuclear cells. Their phenotype and function were analyzed in healthy and IBD-inflamed gut tissues. In the healthy gut, cDC2 predominated over cDC1, with CD103+ cDC2 dominating the duodenum and CD103- cDC2 prevalent in the ileum and colon. CD103+ cDC2 expressed higher PD-L1 and produced more IL-10. In culture, CD103+ cDC2 increased proportionally unless inhibited by LPS. All subsets induced IL-10+ helper T-cell differentiation, with ileal cDCs being more stimulatory than colonic ones. In IBD, cDCs showed constitutively lower SIRPα expression across conditions. Notably, UC-inflamed colon exhibited reduced cDC1 and CD103+ cDC2, while CD-inflamed colon maintained these subsets but showed increased T-cell stimulation and IL-17+ T-cell priming. Intestinal cDC subsets prime IL-10+ helper T-cells in health. In UC, reduced cDC1 and CD103+ cDC2 in inflamed mucosa contrast with CD, suggesting distinct pathogenic mechanisms that could inform targeted therapies.
- Open Access
- 4 November 2025
- Published by Wiley in Microbiologyopen
- Vol. 14 (6) , e70088
Fungal‐Bacterial Dysbiosis in IBD: Microbial Biomarkers of Disease Activity
Inflammatory bowel disease is associated with complex changes in the intestinal microbiota. While bacterial dysbiosis has been widely studied, the role of fungal communities and their interaction with bacteria remains less explored. This study aims to characterize both bacterial and fungal populations in patients with Crohn's disease and ulcerative colitis, identifying potential microbial biomarkers and inter‐kingdom interactions related to disease activity. We analysed paired intestinal tissue and faecal samples from patients with inflammatory bowel disease. Bacterial, fungal and viral composition were assessed by 16S, ITS DNA and shotgun sequencing, respectively. Bioinformatics analyses were done using Qiime2 and R studio platforms. PERMANOVA and ANOSIM analyses revealed significant compositional differences between faecal and mucosal samples in most groups. Several genera were consistently shared across tissues, while others showed tissue‐ or disease‐specific distributions. Exploratory correlations between bacteria and fungi revealed that Wallemia could play a role in balancing the presence of potentially beneficial and pathogenic bacteria. Importantly, Prevotella was associated with active disease, Fusobacterium with active Crohn's disease, and Roseburia with remission in ulcerative colitis, supporting their potential as biomarkers. All these hypotheses should be further tested in future studies. Our findings reveal distinct microbial signatures in inflammatory bowel disease that could promote the intestinal dysbiosis hypotheses perpetuate chronic intestinal inflammation. The identification of faecal biomarkers may complement approaches for noninvasive monitoring of disease activity. These results underscore the need for further research into bacteria‐fungi interactions and their role in gut inflammation.
- 4 November 2025
- Published by Wiley in Microbiologyopen
- Vol. 14 (6) , e70088
Open AccessFungal‐Bacterial Dysbiosis in IBD: Microbial Biomarkers of Disease Activity
Inflammatory bowel disease is associated with complex changes in the intestinal microbiota. While bacterial dysbiosis has been widely studied, the role of fungal communities and their interaction with bacteria remains less explored. This study aims to characterize both bacterial and fungal populations in patients with Crohn's disease and ulcerative colitis, identifying potential microbial biomarkers and inter‐kingdom interactions related to disease activity. We analysed paired intestinal tissue and faecal samples from patients with inflammatory bowel disease. Bacterial, fungal and viral composition were assessed by 16S, ITS DNA and shotgun sequencing, respectively. Bioinformatics analyses were done using Qiime2 and R studio platforms. PERMANOVA and ANOSIM analyses revealed significant compositional differences between faecal and mucosal samples in most groups. Several genera were consistently shared across tissues, while others showed tissue‐ or disease‐specific distributions. Exploratory correlations between bacteria and fungi revealed that Wallemia could play a role in balancing the presence of potentially beneficial and pathogenic bacteria. Importantly, Prevotella was associated with active disease, Fusobacterium with active Crohn's disease, and Roseburia with remission in ulcerative colitis, supporting their potential as biomarkers. All these hypotheses should be further tested in future studies. Our findings reveal distinct microbial signatures in inflammatory bowel disease that could promote the intestinal dysbiosis hypotheses perpetuate chronic intestinal inflammation. The identification of faecal biomarkers may complement approaches for noninvasive monitoring of disease activity. These results underscore the need for further research into bacteria‐fungi interactions and their role in gut inflammation.
- Open Access
- 22 January 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 10, 100271
Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function
- 22 January 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 10, 100271
Open AccessTofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function
- Open Access
- 21 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11070
Altered Surface Expression of Insulin-Degrading Enzyme on Monocytes and Lymphocytes from COVID-19 Patients Both at Diagnosis and after Hospital Discharge
Although the COVID-19 disease has developed into a worldwide pandemic, its pathophysiology remains to be fully understood. Insulin-degrading enzyme (IDE), a zinc-metalloprotease with a high affinity for insulin, has been found in the interactomes of multiple SARS-CoV-2 proteins. However, the relevance of IDE in the innate and adaptative immune responses elicited by circulating peripheral blood mononuclear cells is unknown. Here, we show that IDE is highly expressed on the surface of circulating monocytes, T-cells (both CD4+ and CD4−), and, to a lower extent, in B-cells from healthy controls. Notably, IDE’s surface expression was upregulated on monocytes from COVID-19 patients at diagnosis, and it was increased in more severe patients. However, IDE’s surface expression was downregulated (relative to healthy controls) 3 months after hospital discharge in all the studied immune subsets, with this effect being more pronounced in males than in females, and thus it was sex-dependent. Additionally, IDE levels in monocytes, CD4+ T-cells, and CD4− T-cells were inversely correlated with circulating insulin levels in COVID-19 patients (both at diagnosis and after hospital discharge). Of note, high glucose and insulin levels downregulated IDE surface expression by ~30% in the monocytes isolated from healthy donors, without affecting its expression in CD4+ T-cells and CD4− T-cells. In conclusion, our studies reveal the sex- and metabolism-dependent regulation of IDE in monocytes, suggesting that its regulation might be important for the recruitment of immune cells to the site of infection, as well as for glucometabolic control, in COVID-19 patients.
- 21 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11070
Open AccessAltered Surface Expression of Insulin-Degrading Enzyme on Monocytes and Lymphocytes from COVID-19 Patients Both at Diagnosis and after Hospital Discharge
Although the COVID-19 disease has developed into a worldwide pandemic, its pathophysiology remains to be fully understood. Insulin-degrading enzyme (IDE), a zinc-metalloprotease with a high affinity for insulin, has been found in the interactomes of multiple SARS-CoV-2 proteins. However, the relevance of IDE in the innate and adaptative immune responses elicited by circulating peripheral blood mononuclear cells is unknown. Here, we show that IDE is highly expressed on the surface of circulating monocytes, T-cells (both CD4+ and CD4−), and, to a lower extent, in B-cells from healthy controls. Notably, IDE’s surface expression was upregulated on monocytes from COVID-19 patients at diagnosis, and it was increased in more severe patients. However, IDE’s surface expression was downregulated (relative to healthy controls) 3 months after hospital discharge in all the studied immune subsets, with this effect being more pronounced in males than in females, and thus it was sex-dependent. Additionally, IDE levels in monocytes, CD4+ T-cells, and CD4− T-cells were inversely correlated with circulating insulin levels in COVID-19 patients (both at diagnosis and after hospital discharge). Of note, high glucose and insulin levels downregulated IDE surface expression by ~30% in the monocytes isolated from healthy donors, without affecting its expression in CD4+ T-cells and CD4− T-cells. In conclusion, our studies reveal the sex- and metabolism-dependent regulation of IDE in monocytes, suggesting that its regulation might be important for the recruitment of immune cells to the site of infection, as well as for glucometabolic control, in COVID-19 patients.
- Open Access
- 20 July 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (7) , 681
Evaluation of Cytokines as Robust Diagnostic Biomarkers for COVID-19 Detection
Antigen tests or polymerase chain reaction (PCR) amplification are currently COVID-19 diagnostic tools. However, developing complementary diagnosis tools is mandatory. Thus, we performed a plasma cytokine array in COVID-19 patients to identify novel diagnostic biomarkers. A discovery–validation study in two independent prospective cohorts was performed. The discovery cohort included 136 COVID-19 and non-COVID-19 patients recruited consecutively from 24 March to 11 April 2020. Forty-five cytokines’ quantification by the MAGPIX system (Luminex Corp., Austin, TX, USA) was performed in plasma samples. The validation cohort included 117 patients recruited consecutively from 15 to 25 April 2020 for validating results by ELISA. COVID-19 patients showed different levels of multiple cytokines compared to non-COVID-19 patients. A single chemokine, IP-10, accurately identified COVID-19 patients who required hospital admission (AUC: 0.962; 95%CI (0.933–0.992); p < 0.001)). The results were validated in an independent cohort by multivariable analysis (OR: 25.573; 95%CI (8.127–80.469); p < 0.001) and AUROC (AUC: 0.900; 95%CI (0.846–0.954); p < 0.001). Moreover, showing IP-10 plasma levels over 173.35 pg/mL identified COVID-19 with higher sensitivity (86.20%) than the first SARS-CoV-2 PCR. Our discover–validation study identified IP-10 as a robust biomarker in clinical practice for COVID-19 diagnosis at hospital. Therefore, IP-10 could be used as a complementary tool in clinical practice, especially in emergency departments.
- 20 July 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (7) , 681
Open AccessEvaluation of Cytokines as Robust Diagnostic Biomarkers for COVID-19 Detection
Antigen tests or polymerase chain reaction (PCR) amplification are currently COVID-19 diagnostic tools. However, developing complementary diagnosis tools is mandatory. Thus, we performed a plasma cytokine array in COVID-19 patients to identify novel diagnostic biomarkers. A discovery–validation study in two independent prospective cohorts was performed. The discovery cohort included 136 COVID-19 and non-COVID-19 patients recruited consecutively from 24 March to 11 April 2020. Forty-five cytokines’ quantification by the MAGPIX system (Luminex Corp., Austin, TX, USA) was performed in plasma samples. The validation cohort included 117 patients recruited consecutively from 15 to 25 April 2020 for validating results by ELISA. COVID-19 patients showed different levels of multiple cytokines compared to non-COVID-19 patients. A single chemokine, IP-10, accurately identified COVID-19 patients who required hospital admission (AUC: 0.962; 95%CI (0.933–0.992); p < 0.001)). The results were validated in an independent cohort by multivariable analysis (OR: 25.573; 95%CI (8.127–80.469); p < 0.001) and AUROC (AUC: 0.900; 95%CI (0.846–0.954); p < 0.001). Moreover, showing IP-10 plasma levels over 173.35 pg/mL identified COVID-19 with higher sensitivity (86.20%) than the first SARS-CoV-2 PCR. Our discover–validation study identified IP-10 as a robust biomarker in clinical practice for COVID-19 diagnosis at hospital. Therefore, IP-10 could be used as a complementary tool in clinical practice, especially in emergency departments.
- Open Access
- 26 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (4) , 335
Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome
Background: Growth arrest-specific factor 6 (GAS6) and the Tyro3, AXL, and MERTK (TAM) receptors counterbalance pro-inflammatory responses. AXL is a candidate receptor for SARS-CoV-2, particularly in the respiratory system, and the GAS6/AXL axis is targeted in current clinical trials against COVID-19. However, GAS6 and TAMs have not been evaluated in COVID-19 patients at emergency admission. Methods: Plasma GAS6, AXL, and MERTK were analyzed in 132 patients consecutively admitted to the emergency ward during the first peak of COVID-19. Results: GAS6 levels were higher in the SARS-CoV-2-positive patients, increasing progressively with the severity of the disease. Patients with initial GAS6 at the highest quartile had the worst outcome, with a 3-month survival of 65%, compared to a 90% survival for the rest. Soluble AXL exhibited higher plasma concentration in deceased patients, without significant differences in MERTK among SARS-CoV-2-positive groups. GAS6 mRNA was mainly expressed in alveolar cells and AXL in airway macrophages. Remarkably, THP-1 human macrophage differentiation neatly induces AXL, and its inhibition (bemcentinib) reduced cytokine production in human macrophages after LPS challenge. Conclusions: Plasma GAS6 and AXL levels reflect COVID-19 severity and could be early markers of disease prognosis, supporting a relevant role of the GAS6/AXL system in the immune response in COVID-19.
- 26 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (4) , 335
Open AccessGrowth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome
Background: Growth arrest-specific factor 6 (GAS6) and the Tyro3, AXL, and MERTK (TAM) receptors counterbalance pro-inflammatory responses. AXL is a candidate receptor for SARS-CoV-2, particularly in the respiratory system, and the GAS6/AXL axis is targeted in current clinical trials against COVID-19. However, GAS6 and TAMs have not been evaluated in COVID-19 patients at emergency admission. Methods: Plasma GAS6, AXL, and MERTK were analyzed in 132 patients consecutively admitted to the emergency ward during the first peak of COVID-19. Results: GAS6 levels were higher in the SARS-CoV-2-positive patients, increasing progressively with the severity of the disease. Patients with initial GAS6 at the highest quartile had the worst outcome, with a 3-month survival of 65%, compared to a 90% survival for the rest. Soluble AXL exhibited higher plasma concentration in deceased patients, without significant differences in MERTK among SARS-CoV-2-positive groups. GAS6 mRNA was mainly expressed in alveolar cells and AXL in airway macrophages. Remarkably, THP-1 human macrophage differentiation neatly induces AXL, and its inhibition (bemcentinib) reduced cytokine production in human macrophages after LPS challenge. Conclusions: Plasma GAS6 and AXL levels reflect COVID-19 severity and could be early markers of disease prognosis, supporting a relevant role of the GAS6/AXL system in the immune response in COVID-19.
- 1 January 2021
- Published by Elsevier
- Vol. 358, 85-104
Human intestinal dendritic cell and macrophage subsets in coeliac disease
- 1 January 2021
- Published by Elsevier
- Vol. 358, 85-104
Human intestinal dendritic cell and macrophage subsets in coeliac disease